Abstract
The lack of low molecular weight (LMW) ligands for the Thyroid Stimulating Hormone Receptor (TSHR) motivated us to initiate a project for the design of such small ligands. Orally active small agonists might replace injected recombinant TSH in the diagnostic screening of thyroid cancer and small antagonists may have therapeutic potential for TSHR-mediated hyperthyroidism (Graves' Disease).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Experimental and Clinical Endocrinology & Diabetes
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
